Phase I Study in Advanced HIV-Associated Solid Tumors, with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Brief description of study
You are being asked to participate in this research study because you are an HIV-positive patient with an incurable cancer for which no standard therapy is available or you were diagnosed with Hodgkin lymphoma and it came back after standard therapy (relapsed). You may have already been treated with chemotherapy, radiation therapy or other treatments, and your disease is now growing. Your participation is voluntary, which means you can choose whether or not you want to participate.
Detailed description of study
The main purpose of this study is to first test the safety of giving nivolumab alone and then in combination with ipilimumab in HIV-positive people with incurable cancers or relapsed Hodgkin lymphoma. We would also like to find out what effects, good and/or bad, this combination of drugs may have on your cancer. The FDA approved nivolumab to treat melanoma, non-small cell lung cancer, and Hodgkin lymphoma and approved ipilimumab to treat advanced melanoma. The combination of nivolumab and ipilimumab is considered to be investigational because it is not approved for use with your type of cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
HIV,hodgkin lymphoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
05 Jul 2023.
Study ID: AMC-095
